Suppliers for the Pharmaceutical Drug: Posaconazole
Last updated: February 20, 2026
Who are the primary manufacturers and suppliers of posaconazole?
Posaconazole, marketed primarily under the brand name Noxafil, is an antifungal medication used for prophylaxis and treatment of invasive fungal infections. It is marketed by several pharmaceutical companies, either directly or through authorized licensees.
Major Suppliers and Manufacturers
Company
Type
Marketed Brand(s)
Manufacturing Locations
Notable Details
Merck & Co. (MSD)
Proprietary, global leader
Noxafil
United States, manufacturing sites globally
Pioneered the drug's development, holds key patents.
Pfizer (formerly Schering-Plough)
Former producer, now Merck licensee
Noxafil, related formulations
Global manufacturing facilities
Previously commercialized, transitioned to Merck licensing.
Dr. Reddy’s Laboratories
Third-party manufacturer, generic
Posaconazole generics
India, other countries
Produces generic versions, often for markets outside US and EU.
Cipla
Generic manufacturer
Posaconazole generics
India
Supplies formulations for emerging markets.
Sun Pharmaceutical Industries
Generic manufacturer
Posaconazole generics
India, globally
Supplies US and international markets in generic form.
Supply Chain Sources and Distribution
Authorized Generics: Companies like Dr. Reddy’s and Cipla produce generic versions mainly for markets outside the US or after patent expiry.
Active Pharmaceutical Ingredient (API): Most suppliers source the API from specialized chemical producers or manufacture it in-house at large-scale facilities.
Finished Dosage Forms: The finished drug is assembled, packaged, and distributed globally through licensed distribution networks, primarily managed by the brand owner—Merck & Co.
Patent and Licensing Considerations
Merck’s patent protections for Noxafil, filed in multiple jurisdictions, typically expire in the early to mid-2020s, leading to increased generic market entries.
A wave of generics is expected to flood markets post-patent expiration, with Indian manufacturers poised to occupy significant market share due to lower-cost manufacturing.
Regulatory Approvals and Market Presence
Region
Patent Status
Key Regulatory Body
Comments
United States
Patent expired (2016)
FDA
Generics available since late 2010s
European Union
Patent expired (2017)
EMA
Multiple generics approved
India
No patent barriers (2016)
CDSCO
Several generics marketed
Japan
Patent protection until 2024
PMDA
Upcoming generic entries expected
Market Trends and Future Supply Outlook
The global antifungal market is projected to grow at a CAGR of approximately 5.3% from 2022-2028.
Increased generic competition after patent expiry is expected to reduce prices and expand availability.
Supply chain vulnerabilities could occur due to raw material shortages, manufacturing quality concerns, or geopolitical factors.
References
U.S. Food and Drug Administration (FDA). "Noxafil (Posaconazole)". (2022).
European Medicines Agency (EMA). "Market authorization for Posaconazole". (2022).
Indian pharmaceutical regulatory database. "Cipla and Dr. Reddy’s Posaconazole information". (2022).
Market research reports on antifungal drugs, 2022.
